Bioresorbable scaffolds: rationale, current status, challenges, and future

Current generation of drug-eluting stents has significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the...

Full description

Saved in:
Bibliographic Details
Published inEuropean heart journal Vol. 35; no. 12; pp. 765 - 776
Main Authors Iqbal, Javaid, Onuma, Yoshinobu, Ormiston, John, Abizaid, Alexandre, Waksman, Ron, Serruys, Patrick
Format Journal Article
LanguageEnglish
Published England 01.03.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Current generation of drug-eluting stents has significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, and neoatherosclerosis. The permanent stents also indefinitely impair the physiological vasomotor function of the vessel and future potential of grafting the stented segment. Bioresorbable scaffolds (BRSs) have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress, and mechanotransduction. While a number of BRSs are under development, two devices with substantial clinical data have already received a Conformité Européenne marking. This review article presents the current status of these devices and evaluates the challenges that need to be overcome before BRSs can become the workhorse device in coronary intervention.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/eht542